Acorda Therapeutics (ACOR) CFO Rogers Resigns

October 4, 2016 6:02 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Chief Financial Officer Michael Rogers has left the company. David Lawrence, Acorda’s Chief of Business Operations, has assumed the role of Chief, Business Operations and Principal Accounting Officer. Andrew Hindman, Acorda’s Chief Business Development Officer, has assumed responsibility for Financial Planning and Analysis and Investor Relations. Mr. Rogers will serve as a consultant to the Company through the end of the year as part of this transition.

“We thank Mike for his many contributions to Acorda during his tenure. He was a key part of the team responsible for the acquisitions of Civitas and Biotie, which have helped position Acorda as a leader in Parkinson’s disease therapeutic development,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. “Mike has been commuting from Boston throughout his years at Acorda, which has been challenging for him and his family. I’m grateful for his dedication to the Company during this time.”

“I also want to thank Dave Lawrence and Andrew Hindman for taking on additional responsibilities within the Company. Dave led our accounting and finance teams for many years, and Andrew has a strong financial background and long-standing relationships with many of Acorda’s investors.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Changes, Management Comments

Related Entities

Definitive Agreement

Add Your Comment